Marksans Pharma announced that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company located in Vema, Goa, India from 9 April 2024 to 17 April 2024.On conclusion of the inspection, the Company has received 5 inspectional observations in form 483. There is no data integrity observation. The Company will work closely with the USFDA and is committed to address these observations comprehensively within the stipulated time.Powered by Capital Market - Live News

Net profit of Marksans Pharma rose 31.27% to Rs 83.24 crore in the quarter ended December 2023 as against Rs 63.41 crore during the previous quarter ended December 2022. Sales rose 22.15% to Rs 586.13 crore in the quarter ended December 2023 as against Rs 479.83 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales586.13479.83 22 OPM %22.6915.97 - PBDT134.6691.94 46 PBT112.6679.20 42 NP83.2463.41 31 Powered by Capital Market - Live News

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 13 February 2024.Powered by Capital Market - Live News

Marksans Pharma has received upgrade in credit ratings for bank facilities from India Ratings and Research as under:Fund based limits (Rs 100 crore) - IND A+/ Positive Non fund based limits (Rs 77 crore) - IND A1+Powered by Capital Market - Live News

Net profit of Marksans Pharma rose 36.36% to Rs 83.52 crore in the quarter ended September 2023 as against Rs 61.25 crore during the previous quarter ended September 2022. Sales rose 17.38% to Rs 531.24 crore in the quarter ended September 2023 as against Rs 452.57 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales531.24452.57 17 OPM %21.4517.74 - PBDT131.3291.88 43 PBT113.7777.83 46 NP83.5261.25 36 Powered by Capital Market - Live News